18
November

06:00 PM EST

Building Data Foundations Early in Drug Discovery & Preclinical Development

Boston Chops Downtown, Boston

What You’ll Gain

In early drug discovery and preclinical development, the focus is often on speed and scientific exploration. But delaying process documentation and data integration can create downstream inefficiencies that are costly and difficult to reverse.

Capturing and structuring data early – across target characterization, validation, and safety profiling – not only improves reproducibility but also sets the stage for scalable, efficient development. By embedding digital intelligence into discovery workflows, organizations can:

-Document processes earlier to reduce rework and improve tech transfer

-Strengthen data integrity for confident decision-making

-Enable AI and automation with structured, contextualized data

-Accelerate innovation by connecting experimental and process insights

Join us to explore how early-stage teams can unlock long-term value by investing in data excellence from the start.

Our Agenda

Why you should attend

Join us for an insightful discussion on achieving data excellence in drug development. Together, we can explore strategies to enhance efficiency and innovation with digital intelligence in your organization.

Meet our Speakers

Sean Stowe, PhD

Principal Solutions Consultant IDBS

Yogesh Lakhotia

Solutions Manager Elucidata

Kelly Doering

Consulting Industry Analyst Axendia, Inc.

Kelly Doering is currently a Consulting Industry Analyst with Axendia, Inc., where she lends her life sciences expertise on laboratory and manufacturing operations and the integration of digital technologies. Kelly previously led the Strategic Marketing team for the Pharmaceuticals Business Unit at Aspen Technology and has held numerous global roles in product development, product management, technical marketing and business development during her tenure at ALPCO and Waters Corporation, respectively. Kelly completed a postdoctoral fellowship in the department of Endocrinology at Boston Children’s Hospital where she studied diet-induced changes in body composition in mice on low and high glycemic index diets. Kelly earned an MS and PhD in nutrient regulation of gene expression from the University of Connecticut, and a BS in Health Sciences and Natural Sciences from Worcester State University. Kelly was elected to the ISPE Boston Chapter’s Board of Directors in 2025 and has been an active ISPE member and volunteer since 2021, organizing and moderating numerous virtual and in-person events. She is passionate about celebrating STEM learners of all ages and volunteers locally as a tutor and mentor.

Reza Nemati

Senior Principal Scientist Novo Nordisk

More about IDBS

More information

IDBS helps BioPharma organizations unlock the potential of AI/ML to improve the lives of patients. As a trusted long-term partner to 80% of the top 20 global BioPharma companies*, IDBS delivers powerful cloud software and services specifically designed to meet the evolving needs of the BioPharma sector. IDBS, a Danaher company, leverages 35 years of scientific informatics expertise to help organizations design, execute and orchestrate processes, manage, contextualize and structure data and gain valuable insights throughout the product lifecycle, from R&D through manufacturing. Known for its signature IDBS E-WorkBook software, IDBS has extended its flexible, scalable solutions to the IDBS Polar and PIMS cloud platforms to help scientists make smarter decisions with assured confidence in both GxP and non-GxP environments. *Rank measured by Market Cap, Q1 2024. Learn more at www.idbs.com

Further Information

Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch

Here To Help

Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D IDBS

IDBS – Building Data Foundations Early in Drug Discovery & Preclinical Development 2025

Building Data Foundations Early in Drug Discovery & Preclinical Development

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%2012%2016'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Boston Chops Downtown, Boston

Our Agenda

Welcome & Networking

Expert Panel Discussion

Dinner Transition

Roundtable Discussions Over Dinner

Group Sharing & Key Takeaways

Closing Remarks

Why you should attend

Meet our Speakers

Sean Stowe, PhD

Yogesh Lakhotia

Kelly Doering

Reza Nemati

More about IDBS

Further Information

Here To Help

Select days you wish to attend You can add multiple days

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Oncology

Vaccines

Haematology

Ophthalmology

Thrombosis

Rare Diseases

This is required field*

0-10

10-50

50-100

100-500

500+

This is required field*

This is required field*

Under £100,000

£100,000 - £500,000

£500,000 - £1,000,000

£1,000,000 - £5,000,000

£5,000,000 - £10,000,000

£10,000,000 +

This is required field*

This is required field*

Discovery to Development

Boston Chops Downtown, Boston